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Background: In a stable of eight horses in Northern Iceland, six horses presented with clinical signs, such as ataxia
and reduced appetite, leading to euthanasia of one severely affected horse. Serological investigations revealed no
evidence of active equine herpes virus type 1 infection, a common source of central nervous system disease in
horses, nor equine arteritis virus and West Nile virus. Another neurotropic virus, Borna disease virus, was therefore
included in the differential diagnosis list.
Findings: Serological investigations revealed antibodies against Borna disease virus in four of five horses with
neurological signs in the affected stable. One horse without clinical signs was seronegative. Four clinically healthy
horses in the stable that arrived and were sampled one year after the outbreak were found seronegative, whereas
one of four investigated healthy horses in an unaffected stable was seropositive.
Conclusions: This report contains the first evidence of antibodies to Borna disease virus in Iceland. Whether Borna
disease virus was the cause of the neurological signs could however not be confirmed by pathology or molecular
detection of the virus. As Iceland has very restricted legislation regarding animal imports, the questions of how this
virus has entered the country and to what extent markers of Bornavirus infection can be found in humans and
animals in Iceland remain to be answered.
Keywords: Borna disease, Neurological disease, Serology, Epidemiology, HorseFindings
Borna disease virus (BDV) is a negative-stranded RNA-
virus infecting and causing neurological disease in several
warm-blooded animals [1,2]. The clinical signs in horses
usually start with disturbances in feed intake, fever and
various degrees of somnolence. Later, ataxia, and other
gait disturbances, more severe somnolence and finally par-
alysis of extremities and head develop (reviewed in [2]).
Other mental changes are also common, such as depres-
sion, coma and excitations. The virus transmission routes
are still obscure, but the involvement of reservoir hosts,
such as wild birds, rodents and insectivores, has been pro-
posed [1,3-5]. Most cases of equine Borna disease (BD)
have been reported from Central Europe; however, BDV-* Correspondence: Jonas.Wensman@slu.se
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distribution, and reproduction in any mediuminfection markers have been reported all over the world
[1]. Avian Bornavirus (ABV) was recently found to cause
proventricular dilatation disease in psittacine and other
avian species, increasing the host spectrum and spread of
these intriguing viruses [1-3].
Here, we describe the first evidence of antibodies to
BDV in Iceland, detected in an outbreak of neurological
disease in horses.
In a geographically isolated fishing village in northern
Iceland there is a cluster of twelve stables that house about
70–80 horses during the winter. In February 2011, one of
the stables (stable A) with 8 horses reported neurological
signs in horses (for details see Table 1). The clinical signs
started in a 21-year-old gelding (horse no. 1) that pre-
sented with pelvic limb ataxia and reduced appetite. Nor-
mal body temperature and full consciousness was
recorded at first day of clinical signs (day 0) in this horse.
After 3–4 days of treatment (Table 1), the horse (no. 1)
improved temporarily; however, after another week it de-
veloped more severe ataxia and loss of appetite, finallyntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical signs and history of horses in the affected stable (stable A)
Horse ID/age Day 0 Day 7 Day 14 Day 21
1. Ataxia and reduced appetite Temporary improvements Severe ataxia/paralysis and loss of appetite Euthanized
21 y Treatment 1a at day 4 Treatment 2b
2.c No clinical signs No clinical signs Ataxia, depression and reduced appetite Slow recovery
21 y Treatment 2b
3. No clinical signs No clinical signs Ataxia, mild excitation and reduced appetite Slow recovery
12 y Treatment 2b
4. No clinical signs No clinical signs Ataxia, mild excitation and reduced appetite Slow recovery
18 y Treatment 2b
5. No clinical signs No clinical signs Mild signs of ataxia and excitation Recovery
13 y Treatment 2b
6. No clinical signs No clinical signs Mild signs of ataxia Recovery
6 y Treatment 2b
7. No clinical signs No clinical signs No clear signs Recovery
9 y Treatment 2b
8. Arrived to the stable 10 days earlier.
No clinical signs
No clinical signs No clinical signs No clinical signs
aTreatment 1 is dexamethasone 20 mg/day for 6 days i.m., procaine benzyl penicillin 4000 mg/day for 6 days i.m.
bTreatment 2 is oxytetracycline 4000 mg i.v. once, glucose 30% 1000 ml i.v. once, metamizole 1500 mg i.v. once, dexamethasone 20 mg/day i.m. daily for 8 days,
ampicillin 1.67 g/day i.m. daily for 6 days, with additional support: medical coal p.o. daily for 8 days, Prolac AB p.o. daily for 6 days, Pro-Bran (Protexin, Probiotics,
Somerset, UK) p.o. daily for 12 days, Ferro Complex (Blue Hors, Randbøl, Denmark) p.o. for 1 month.
cThis horse was euthanized approx. 6 months after the onset of signs, because of age and a history of intermittent lameness, most likely independent of the
neurological signs.
Björnsdóttir et al. Acta Veterinaria Scandinavica 2013, 55:77 Page 2 of 4
http://www.actavetscand.com/content/55/1/77becoming paralysed in its pelvic limbs and was euthanized
(day 21). At this time-point (day 13–14), five other horses
(horses no. 2–6) were also affected, showing various de-
grees of pelvic limb ataxia, depression or excitation and re-
duced appetite (Table 1). The body temperature of all
horses was found to be within the normal range. As the
horses were examined under field conditions, a detailed
neurological status was, however, not achieved. All horses,
except for one mare (horse no. 8) that showed no clinical
signs and had arrived 10 days before the time of onset of
clinical signs in horse no. 1 (day −10), were treated as indi-
cated in Table 1. Horses no. 5–6 recovered by day 21, while
horses no. 2–4 had a slow recovery and were only fully re-
covered around 3 months after onset of signs in the index
case. Horse no. 2 was euthanized approximately 6 months
after onset of signs due to age and a history of intermittent
lameness, most likely independent of the neurological signs.
Horse no. 8 did not show any clinical signs throughout the
whole observation period (until day 440).
Initially, serum samples from four of the horses (horses
no. 2, 3, 5 and 6) were taken for serological analyses 9–10
days after they presented with neurological signs and three
weeks after onset of signs in the index case (day 23). No
antibodies towards equine herpes virus (EHV) types 1 and
4 were found by complement fixation. Presence of IgG-
antibodies against EHV-1 detected by ELISA (Svanovir
EHV1/EHV4-Ab, Svanova, Uppsala, Sweden) in one horse
(no. 5) was not regarded to indicate an active EHV-1infection and none of the other investigated horses in the
outbreak stable had this finding in the observation period
(from day 23 to 440). Antibodies to equine arteritis virus
(EAV) and West Nile virus (WNV) were not detected by
serum neutralization test and ELISA (ID Screen West Nile
Competition, ID-vet, Montpellier, France), respectively. In-
fection with an alphavirus was considered unlikely based
on the clinical signs and epidemiology. We therefore de-
cided to include BDV as a differential diagnosis.
An indirect immunofluorescence assay (IFA) was
employed as previously described [6], except for the use of
fluorescein isothiocyanate (FITC) conjugated anti-horse
IgG antibodies as secondary antibodies. Horse sera previ-
ously characterised as positive or negative for BDV anti-
bodies in a BDV-ELISA were used as controls, whereof
one of the positive controls also was PCR-positive and
positive at Western blotting [7]. Serum incubation on
slides with non-infected cells was used as negative con-
trols, to exclude the possibility for unspecific fluorescence
signals due to cross-reactivity. All serum samples were
sent for a second IFA analysis [8] (Idexx/Vet Med Labor,
Ludwigsburg, Germany). An individual sample was con-
sidered seropositive if a titre of ≥1:40 was detected in both
IFAs, negative if both titres were <1:40, and doubtful if
only one of the IFAs showed a titre of ≥1:40.
Around 10 days after onset of clinical signs, all horses
showing clinical signs (horses no. 2–5) were positive in
the first IFA, and two of the horses (horses no. 2 and 5)
Table 2 BDV serology of horses in the affected stable A
Horse ID Clinical signsa (see Table 1) Day 23 (IFA1b/IFA2c) Approx. day 380 (IFA1b/IFA2c) Approx. day 440 (IFA1b/IFA2c)d
1. ++++ n.d.e n.d. n.d.
2. ++++ 1:160/1:80 n.d. n.d.
3. ++ 1:80/<1:10 1:40/<1:10 1:160/1:40
4. ++ n.d. n.d. <1:20/1:40
5. + 1:160/1:40 1:320/<1:10 1:160/<1:10
6. + 1:80/<1:10 1:160/1:40 n.d.
7. (+) n.d. n.d. 1:160/1:40
8. - n.d. n.d. <1:20/<1:10
aThe degree of clinical signs is indicated as ++++ = severe clinical signs, ++ = moderate signs, + = mild signs, and (+) = no clear signs.
bIFA1 is the IFA performed in Sweden.
cIFA2 is the IFA performed in Germany.
dSamples were blindly tested.
en.d. indicates not done.
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positive (Table 2). These results led to an increased
monitoring of the horses in the affected stable (Tables 2
and 3). Blood and serum samples were collected 380–
440 days after the outbreak from 3 of the 4 horses ini-
tially tested. Additionally, blood samples were collected
from 6 other horses in stable A. Three of these 6 horses
had been in the stable at the time of the outbreak (Tables 2
and 3). The horses were either seropositive (no. 2, 3, 5–7)
or doubtful seropositive (no. 4) for BDV-antibodies
(Table 2). No BDV-specific antibodies were detected in
horse no. 8 that arrived to the stable at day −10, indicating
that BDV entered the stable before that time. This horse
showed no clinical signs throughout the observation
period (until day 440). Likewise, all horses, that were
housed in stable A in 2012 but not in 2011, did not show
any signs of neurological disease and were seronegative
(Table 3). As comparison, horses in another stable (stable
B) with no evidence of neurological disease, situated ap-
proximately 50 km southwest of the affected stable, were
investigated. In stable B one horse had presence of BDV-
specific antibodies, one was seronegative and two wereTable 3 BDV serology of clinically healthy horses
Horse ID/Stable ID IFA1a/IFA2b
9. / A-12 <1:20/<1:10
10. / A-12 <1:20/<1:10
11. / A-12 <1:20/<1:10
12.c / B 1:160/<1:10
13.c / B <1:20/<1:10
14.c/ B 1:160/1:160
15.c/ B 1:40/<1:10
aIFA1 is the IFA performed in Sweden.
bIFA2 is the IFA performed in Germany.
cSamples were blindly tested.
A-12 refers to horses that entered the affected stable the year after the
outbreak (2012). Stable B is situated ca. 50 km southwest of stable A. The two
stables have had no contacts.considered doubtful (Table 3). There were no contacts be-
tween stables A and B.
Molecular diagnostics was performed using previously
described real-time and conventional RT-PCR assays tar-
geting three genes of BDV (P, N and M) [6,9,10]. Total
RNA was extracted from peripheral blood drawn at day
380 from horses no. 3, 5 and 6 as previously described [6];
however, we could not confirm presence of BDV-RNA in
any of the horses.
The euthanized horses were not sent for necropsy; thus,
there are no pathology data confirming inflammatory
changes of the central nervous system indicating virus in-
fection. Nevertheless, this report shows the first evidence
of antibodies to BDV in Iceland, a country with extremely
strict animal import regulations, indicating that these
horses have been exposed to BDV or a closely related virus.
In 1998, we conducted a study of 17 Icelandic horses with
pyrexia of unknown reason, which found all to be sero-
negative by BDV-ELISA (performed at Robert Koch Insti-
tute, Berlin, Germany). How the virus has entered Iceland
remains to be determined. One possible route of transmis-
sion is by migratory birds, because wild birds have been in-
dicated as potential reservoirs of BDV [1,3]. A unique
strain of Bornavirus was recently found in healthy Canada
geese in the USA, indicating that this migrating waterfowl
could carry virus over long distances [11]. Around 60 spe-
cies of migrating birds visit Iceland during April to Octo-
ber. Many of them pass North Iceland, including swans,
geese and loons. The Canada goose is recognised as an an-
nual visitor in spring and autumn, originating both from
Europe and North America [12]. Because of the extremely
rigid animal import regulations of Iceland, migratory birds
are more likely routes of Bornavirus transmission, than do-
mestic animal transports. It has also been proposed that
horses in stables along the paths of migratory birds have
higher seroprevalence than horses in areas absent of migra-
tory birds [13]. As antibodies to both BDV and ABV cross-
react with the strain (He/80) used in the IFAs in our study
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could be ABV or a more avian-like Bornavirus.
In conclusion, we present the first evidence of antibodies
to Bornavirus in Iceland, found in horses with and without
neurological signs. The aetiology of the neurological signs
has not been confirmed, and other causes, such as toxins
or other viruses, cannot be excluded. Acquired equine
polyneuropathy has recently been described in Swedish,
Norwegian and Finnish horses, but this syndrome does
not give rise to ataxia [15]. Hence, it seems unlikely that
the horses in this study suffered from this syndrome. The
questions of how Bornavirus has entered the country and
to what extent markers of Bornavirus infection can
be found in humans and animals in Iceland remain to be
answered.
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